An Invited Review for the Special 20th Anniversary Issue of MRMS

In vivo Human MR Spectroscopy Using a Clinical Scanner: Development, Applications, and Future Prospects

Moyoko Tomiyasu1,2 and Masafumi Harada3*

MR spectroscopy (MRS) is a unique and useful method for noninvasively evaluating biochemical metabolism in human organs and tissues, but its clinical dissemination has been slow and often limited to specialized institutions or hospitals with experts in MRS technology. The number of 3-T clinical MR scanners is now increasing, representing a major opportunity to promote the use of clinical MRS. In this review, we summarize the theoretical background and basic knowledge required to understand the results obtained with MRS and introduce the general consensus on the clinical utility of proton MRS in routine clinical practice. In addition, we present updates to the consensus guidelines on proton MRS published by the members of a working committee of the Japan Society of Magnetic Resonance in Medicine in 2013. Recent research into multinuclear MRS equipped in clinical MR scanners is explained with an eye toward future development. This article seeks to provide an overview of the current status of clinical MRS and to promote the understanding of when it can be useful. In the coming years, MRS-mediated biochemical evaluation is expected to become available for even routine clinical practice.

Keywords: clinical utility, magnetic resonance spectroscopy, metabolite, multi-nuclei

Introduction

In vivo MR spectroscopy (MRS) was initially performed as phosphorus (31P)-MRS, which detects biochemical phosphorus compounds in tissue. These substances, which include adenosine triphosphate, phosphocreatine, and inorganic phosphate, participate in energy metabolism in viable cells, enabling researchers to observe dynamic changes in energy metabolism in vivo in specific settings using this technique. In the late 1980s, in the early stage of clinical MR instrumentation, some high-end clinical MRI machines were equipped with multinuclear systems including specific transmitter and receiver coils, and 31P-MRS could be used in the clinical setting. However, owing to several disadvantages of this technique, including low sensitivity and complicated procedures for changing frequency and receivers, its clinical applications were strictly limited and the technique was not used in routine clinical practice.

Meanwhile, proton MRS (1H-MRS) has been recognized as a useful method for evaluating cerebral metabolism that does not require a change in the frequency and receiver coils after brain MRI studies. Its targeted metabolites are several amino acids, lactate (Lac), creatine, and choline-containing compounds. In particular, n-acetyl aspartate (NAA) exhibits high levels in cerebral neurons. In the early 1990s, the characteristics of NAA were examined, with intense focus on its mechanisms and roles. This amino acid was found to be specific to neurons and to be synthesized through the direct acetylation of aspartate in mitochondria.1 With NAA now considered a neuronal marker, 1H-MRS subsequently started to receive more attention in clinical research and diagnosis than 31P-MRS. In clinical practice, 1H-MRS is sometimes performed to investigate the levels of metabolites and provides additional information for the diagnostic process.

In this review, we focus on MRS performed using a clinical MR scanner, which is divided into three categories: (1) MRS with a clinical MR scanner, (2) the clinical utility of 1H-MRS, and (3) the expected use of other nuclei besides protons in clinical MRS. Although we mainly use single-voxel 1H-MRS in the brain to describe MRS, its principles
and methods may be applicable to MRS data of other anatomical regions, as well as those of other nuclei and MR spectroscopic imaging (MRSI).

**MRS with a Clinical MR Scanner**

*Metabolites observed in human brain $^1$H-MRS*

**Major metabolites**

With *in vivo* $^1$H-MRS of the brain, there are more than 30 observable metabolites, each with a variety of chemical shift value combinations. The heights of each peak are proportional to the number of protons but decrease with longitudinal relaxation time ($T_1$), transverse relaxation time ($T_2$), and J-coupling inherent to each peak, with the degree of the decrease depending on the MRS sequence and its parameters, including TE and TR. However, if the TR is long enough, the peak is not affected by the $T_1$ (see 2.2.3 and 2.4 for more details). Furthermore, for *in vivo* human measurements, line broadening due to magnetic field inhomogeneity can cause peaks to overlap those of other metabolites or the metabolite peaks with low concentrations to be embedded in noise, meaning that about 5 or 6 metabolites can be clearly observed in a clinical MR scanner (Fig. 1). The typical brain metabolites observed by MRS with a 1.5-T or 3-T clinical MR scanner are NAA and N-acetylaspartylglutamate (tNAA); glycerophosphocholine (including choline-containing compounds) and phosphocholine; Cr, creatine and phosphocreatine; Glx, glutamate and glutamine; mIns, myo-inositol; PRESS, point-resolved spectroscopy; tNAA, N-acetylaspartylglutamate.

**Other metabolites**

Metabolites other than those mentioned above include taurine, ethanolamine, gamma aminobutyric acid (GABA), and glutathione (GSH), but these are usually at low concentrations ($\leq 2.0 \text{ mM}$). In healthy individuals, their concentrations are not easy to measure accurately because their metabolite peaks overlap those of metabolites with higher concentrations such as Glu and Gln, but in specific pathological conditions, these metabolites may be identified by an increase in their concentration. In addition, GABA and GSH can be measured using the J-difference editing method (e.g., MEGA-PRESS) with scanners over 2.0 T.

**MR spectral quality in clinical $^1$H MRS**

The spectrum needs to have a good SNR. Improving SNR requires adjustment of the uniformity of the magnetic field, which affects the linewidth of the spectrum, and adjustment of sequence parameters such as TE and TR, voxel size, and the number of signal averages. The spectral quality may also be improved by correcting spectral distortion due to the eddy current effect.
The SNR is defined as the ratio of the largest metabolite peak height to twice the root-mean-square standard deviation of the noise in areas with no peaks and/or artifacts of the spectrum in the frequency domain (Fig. 2). However, it is sometimes defined as the ratio of the largest metabolite peak height to the root-mean-square standard deviation or the free induction decay (FID) signal amplitude at \( t = 0 \) divided by the noise at the end of the FID in the time domain.

**Linewidth**

The full-width at half-maximum (FWHM) of the spectral height is usually used as the definition of linewidth (Fig. 3). The FWHM of a metabolite or water peak is determined by its \( T_2 \) and the local inhomogeneity of the magnetic field (\( \Delta B_0 \)). Furthermore, if the multiplication of any line as a window function is applied to the FID data before the Fourier transform, the related value will also be included in the FWHM of the spectral data.

\[
\text{FWHM} = \frac{1}{\pi T_2} + \gamma \Delta B_0 + \text{(WinFunc)} \quad [1]
\]

Here, \( \gamma \) is the gyromagnetic ratio and WinFunc is related to the multiplied window function value. The \( T_2 \) of the major brain metabolites (tNAA, tCr, tCho, mIns, Glx, and Lac) at 3-T is reported to be 134–318 ms, which means that

\[
\frac{1}{\pi T_2} \quad \text{is calculated to be 1.0–2.4 Hz. To achieve local homogeneity, shimming is performed using a vendor-provided shim tool. Shimming methods include 3D shim, which is based on spherical harmonic analysis, and fast}
\]

---

**Table 1** Brain metabolites typically detected by MRS with a 1.5- or 3-T clinical MR scanner

| Metabolites | Comments |
|-------------|----------|
| tNAA        | NAA is produced in neuronal mitochondria and converted to N-acetylaspartylglutamate or transported to oligodendrocytes as a source of acetyl groups for myelin lipid synthesis. NAA is thought to correlate with the density of normal neurons, and a tNAA peak reduction is observed in many neurological disorders. The main peak from the acetyl group (CH3CO-) is at 2.01 ppm. |
| Cr          | Cr acts as a “battery” for replenishing ATP levels. In adults, its concentration usually remains relatively stable during aging, as well as in a variety of diseases. Hence, it is sometimes used as the denominator of other metabolite ratios. The main peak from the methyl protons of both creatine and phosphocreatine is at 3.03 ppm. |
| Cho         | Cho is involved in various functions in the body, but the primary contributors to the Cho signal detected with \(^1\)H in normal tissue are PCho and GPC, and signal changes are generally associated with alterations in membrane and composition and are thought to often correlate with the destruction or enhancement of cell membrane metabolism. The main peak from the methyl protons of several choline-containing metabolites is at 3.2 ppm. |
| Glx         | Glu is an excitatory neurotransmitter, and Gln is involved in glutamate detoxification, osmolyte synthesis, and ammonia detoxification. At 1.5-T, there is substantial overlap between the Glu and Gln peaks, and it is difficult to separate these peaks with high reliability. The peaks are at about 2.1 to 2.6 ppm. |
| mIns        | mIns is an intracellular osmolyte found in astrocytes and a lipid metabolism precursor for membrane synthesis. Elevated mIns is considered to reflect an increased population of glial cells. It also plays roles in cellular nutrition and forms complexes, such as those with inositol-1-phosphate and phosphatidylinositol. At a short TE (~30 ms), its main peak is at 3.55 ppm and may contain a glycine peak. |
| Lac         | Lac is a metabolite produced by anaerobic glycolysis that is considered to be an indicator of the degree of energy metabolism disorder. Lac peaks in the brain have been observed during diseases such as mitochondrial disorders and are interpreted as an increase in anaerobic metabolism. In the newborn period, Lac peaks are often observed, even under healthy conditions, and it is considered to an important energy source for the brain. The peaks are at about 1.33 ppm, and lipid and/or macromolecule peaks may overlap them at a short TE (~30 ms). |

---

**Fig. 2** Definition of the signal-to-noise ratio in the frequency domain.
automatic shimming technique by mapping along projections (FASTMAP) shimming, which is based on measuring $B_0$ field plots along projections.\textsuperscript{42}

Voxel size, TE and TR, and number of signal averages

Voxel size: This parameter is also known as volume of interest (VOI). The SNR is said to be proportional to the $\text{VOI}^{35}$ but the VOI is preferably 8 mL or less in \textit{in vivo} brain MRS.

TE: A short TE (< 35 ms) avoids a signal decrease due to $T_2$ decay and signal phase modulation due to J-coupling and detects numerous metabolites (Fig. 4). However, macromolecules and/or lipids with a short $T_2$ and J-couplings are also detected as broad peaks (Fig. 4),\textsuperscript{43-45} and these broad peaks may interfere with the quantification of metabolite peaks. At a TE of 144 ms, the lactate peak (1.33 ppm) is inverted owing to the phase modulation by J-coupling (Fig. 5), and in addition, the macromolecules and lipid peaks are relaxed and phase-modulated, resulting in a significant decrease in peak height. Therefore, a TE of 144 ms (or 135 ms) is mainly used for Lac peak evaluation.\textsuperscript{46} A longer TE is used to observe the metabolite peaks of a relatively longer $T_2$.\textsuperscript{47-49} Moreover, for a metabolite with J-couplings between multiple $^1$Hs, the peak is decreased owing to the phase modulations with a longer TE time, as shown in Fig. 5.\textsuperscript{50,51} Therefore, a short TE is required to observe mIns, Glu, and/or Gln, and a TE setting of 144 ms or longer may be used to exclude other metabolites for the evaluation of tNAA, Cr, Cho, and/or Lac (Fig. 4).

TR: As for TR, it should be set to 2000 ms or more to avoid signal loss due to insufficient longitudinal relaxation with a too short TR (see Metabolite quantification for more details).

Number of signal averages: This parameter is also known as the number of excitations (NEX) in MRS. Because the SNR is said to be proportional to the square root of the number of signal averages, if the resulting spectrum does not have a sufficient SNR, an increase in the number of signal averages may give a better result.

Fig. 3 Two representative spectra from \textit{in vivo} human brain MRS. Although the peak of Glu is clearly observed in \textit{a}, it seems difficult to separate the broad peaks into Glu and Gln in \textit{b}. FWHM, full-width at half-maximum; Gln, glutamine; Glu, glutamate; MRS, MR spectroscopy.

Fig. 4 Representative \textit{in vivo} human brain$^1$H-MR spectra with different TEs (30, 144, and 288 ms). Volume, 8 mL; TR, 3000 ms; number of signal averages, 128. Cho, glycerophosphocholine (including choline-containing compounds) and phosphocholine; Cr, creatine and phosphocreatine; Glx, glutamate and glutamine; mIns, myo-inositol; tNAA, N-acetylaspartylglutamate.
Eddy current effect correction
Eddy currents induced by rapid gradient switching generate short-time $B_0$ field fluctuations. If this fluctuation remains during the acquisition window, the FID data are affected by the fluctuation, which leads to MRS signal distortion (Fig. 6). Correction is performed by using a water-unsuppressed signal with an identical VOI, gradient strengths, and timings to the water-suppressed data. The same eddy current effects as the water-unsuppressed data are also included in the phases of the water-suppressed data. By subtracting this phase function from both the water-suppressed and water-unsuppressed FID signals, the spectra can be free from the eddy current effects (Fig. 6).

MRS data acquisition methods
MRS data collection methods include single-voxel MRS and MRSI, which is also called chemical shift imaging (CSI). Furthermore, VOI localization methods include localization by sequences such as point-resolved spectroscopy (PRESS) and stimulated echo (STEAM), which generate a cube, rectangular, or parallelepiped voxel, and localization by a surface coil with a sequence such as depth-resolved sequence (DRESS), which is often used when the target organ or tissue is in a region of the body other than the head and when the target nucleus is a non-proton nucleus, such as $^{13}$C or $^{31}$P.

Water signal suppression and outer volume suppression pulse
Prior to the execution of the localization sequence, water signal suppression and outer volume suppression (OVS) are usually performed, as shown in Fig. 7. Water has a concentration of 10000 times or more than that of metabolites and, in the spectrum, distortion due to water peaks may make it difficult to quantify the metabolite peaks. Therefore, a chemical shift selective (CHESS) pulse is used for the water signal suppression. The CHESS sequence comprises a frequency-selective RF pulse followed by a spoiler gradient. In a clinical MR scanner, three repetitions of CHESS pulses are used to enhance the water suppression effect; because the repetition of CHESS pulses generates unwanted echoes, the direction of the spoiler gradient is switched for each CHESS pulse (Fig. 7a) or its intensity is gradually increased (Fig. 7a). When spectra of an identical VOI with a water-unsuppressed signal are also acquired to correct eddy current-induced phase shifts and quantify metabolite concentrations (see Eddy current effect correction and Metabolite quantification for more details), the CHESS RF pulse is specifically turned off and the spoiler gradient is used as is. OVS is a method for spatially saturating and reducing the signal outside the VOI. The strength of the slice gradient for the saturation pulse should be higher in order to minimize the chemical shift displacements of metabolites.

Single-voxel MRS
STEAM: The STEAM sequence is installed by default on MRI devices capable of MRS. The STEAM sequence uses three $90^\circ$ pulses for localization and generates four to five echoes; the echo generated after the third $90^\circ$ pulse is called the stimulated echo and is used in MRS as the desired signal (Fig. 7c). Spoiler gradients destroy the echoes and FIDs outside the VOI. The interval between the second and third pulses is called the mixing time (TM). During the
TM period, the magnetization is at the longitudinal (z-) axis, has no transverse components, and does not experience T2 decay. Therefore, the effective TE is the sum of the times between the first and second pulses (TE/2), and the third pulse and the signal acquisition (TE/2). The maximum signal intensity of the stimulated echo can be calculated as follows:

\[ S \propto \frac{M_0}{2} \cdot \sin \alpha_1 \cdot \sin \alpha_2 \cdot \sin \alpha_3 \cdot \exp \left( \frac{-TE}{T_2} \right) \cdot \exp \left( \frac{-TM}{T_1} \right), \]

where \( M_0 \) is the equilibrium magnetization along the z-axis and \( \alpha_i \) is the \( i \)th pulse angle. If each pulse is a perfect 90°, and TE and TM are both short enough compared with the T1 and T2, the maximum possible signal is 50% of the \( M_0 \).

PRESS: The PRESS sequence\(^2^8\) is also installed by default on MRI devices capable of MRS. The PRESS sequence comprises mainly three slice-selective pulses (90°–180°–180°), each of which has a field gradient for localization, and a single voxel is finally excited. Spoiler gradients on both sides of the field gradient destroy the echoes and FIDs outside the VOI mainly generated by imperfect RF pulses\(^1^8,2^8,4^1\) (Fig. 7c2).

PRESS is more widely used because its SNR is twice of that of STEAM\(^1^8,7^6\). However, the advantages of STEAM over PRESS are that (i) TE can be shortened in STEAM owing to the difference in the echo generation mechanism described above, and (ii) by using only 90° pulses, it has a sharper slice profile, a wider pulse bandwidth, smaller chemical shift displacements of metabolites, and a smaller specific absorption rate\(^1^8,4^1,7^7\).

### Metabolite quantification

There are several software packages for in vivo MRS data analysis, including LCModel, jMRUI, and Tarquin, all three of which are free to use.\(^7^8,8^3\) Here, we will consider LCModel and describe the output metabolite values. LCModel runs on Unix or Linux and quantitatively analyzes peaks of in vivo brain metabolites, muscle, or liver from the MRS data collected.\(^3^4,7^9\) LCModel uses linear analysis to separate a spectrum into peaks of individual metabolites by comparison with a set of model spectra, called a basis set (see the last paragraph of this section for more details). When FID data are input into the LCModel, preprocessing such as fast Fourier transform and phase correction\(^4^3,5^4,8^4,8^5\) is automatically performed, and the MR spectrum and various items are output, including the quantitative values of each metabolite, Conc., %SD, /Cr+PCr, and Metabolite (Fig. 1). The Conc. values of each metabolite are calculated using the following equation:

\[ \text{Conc.} = \frac{\text{Metabolite peak area}}{\text{Water peak area}} \times \text{Water concentration}, \]

where the metabolite peak area is that of the spectrum of the water-suppressed signal and the water peak area is that of the spectrum of the water-unsuppressed signal obtained from the identical VOI. The calculation process for Conc. does not consider the relaxation of the water and metabolite peaks. However, by default, only the water peak area is multiplied by 0.7, which takes into
account the reduction in the water peak by $T_2$ at $TE = 30$ ms. The correction of the peak relaxation by $T_1$ and $T_2$ for water and metabolites will be discussed later. Water concentration describes the water concentration in the VOI. The default value is 35.88 M, which is that of adult white matter. In addition, a concentration of 43.30 M is listed in the LCModel manual as that of adult gray matter. However, the VOI region may contain a mixture of gray matter, white matter, and CSF, and the ratio of these components must be measured to more accurately determine the water concentration. Moreover, water concentrations vary with age and may be altered in diseases such as edema and some tumors. Therefore, it should be noted that serious errors in the results can occur if metabolite Conc. values are obtained using the same water concentration for different age groups, such as children and adults, or for healthy and disease groups.

Depending on the TE and TR settings, the water and metabolite peaks will decrease with their respective $T_1$ and $T_2$. The peak relaxation by $T_1$ and $T_2$ will be discussed later.

**Fig. 7** An example of a single-voxel MRS scheme (not to scale). a) CHESS pulse for water suppression. b) Outer volume suppression pulse. c1) STEAM sequence. TM = mixing time. c2) PRESS sequence. TE1 = first PRESS echo time; TE2 = second PRESS echo time.
T2 values as follows:

\[
M_{xy} = M_0 \left\{ 1 - \exp\left(-\frac{TR}{T_1}\right) \right\} \cdot \exp\left(-\frac{TE}{T_2}\right),
\]

where \(M_{xy}\) is the magnetization on the xy-transverse plane and \(M_0\) is the equilibrium magnetization along the Z-axis. The first exponential equation is the \(M_0\) recovery rate according to \(T_1\) at \(t = TR\), and the \(M_0 \left\{ 1 - \exp\left(-\frac{TR}{T_1}\right) \right\}\) is equal to the \(M_{xy}\) magnetization just after being inverted to the xy-transverse plane by the 90° excitation pulse. The second exponential equation is the signal decay due to \(T_2\) relaxation after excitation. Therefore, adding to Equation [3] a consideration of the decrease in metabolite and water peaks due to \(T_1\) and \(T_2\), we get the following equation:

\[
\begin{align*}
\frac{\text{Metabolite peak area}}{\text{Metabolite proton numbers}} & \times \text{Water conc.} \\
\frac{\text{Water peak area}}{\text{Water proton numbers}} & \times \left\{ \frac{1 - \exp\left(-\frac{TR}{T_1}\right)}{1 - \exp\left(-\frac{TR}{T_1}\right)} \right\} \exp\left(-\frac{TE}{T_2}\right),
\end{align*}
\]

Equations [4] and [5] show that the combination of a longer \(TR\) and shorter \(TE\) results in a smaller decrease in magnetization. At 1.5- and 3-T, the \(T_1\) of adult brain metabolites is up to about 1.6 s,8,38,93–96 and if the TR is set to 5 s or more, that is, \(1 - \exp\left(-\frac{TR}{T_1}\right) \approx 1\), it is not necessary to consider the correction of magnetization reduction by the \(T_1\). On the other hand, children have a higher brain water concentration and longer \(T_1\) and \(T_2\) compared with adults,8,47,89 and even adults may have a higher water concentration in pathological tissues such as tumors,91 and may therefore need a longer TR setting to ignore the \(T_1\) effect. To avoid the decrease in magnetization due to \(T_2\) (and J-couplings, if present), a shorter \(TE\) is useful,8,38,43,47,49,89,97–102 but this needs to take into account the contribution of the macromolecule peaks (see Voxel size, TE and TR, and number of signal averages for more details). To determine the metabolite concentrations, it may also be necessary to consider the chemical shift displacements of metabolite peaks with different frequencies from the excitation frequency, which is usually set to the water resonance.18,103

The value of %SD is equal to the Cramér–Rao lower bound and is used as an index of the uncertainty in the metabolite concentration estimates.34 The \(\text{Cr+PCr} \) for each metabolite represents the value of its metabolite value displayed in Conc. divided by that of Cr+PCr displayed in Conc.34 The \(\text{Cr+PCr} \) value (i.e., metabolite to Cr+PCr ratio) can be obtained without a water-unsuppressed spectrum and is a simpler method than that for determining the metabolite concentration.

The basis set must be a set of model spectra with the same pulse sequence, TE, and static field strength as the MRS data to be analyzed. Several basic sets are available for common measurement parameters, including TE 30 ms and 144 ms for 1.5-T and 3-T PRESS and STEAM sequences. If there is no basis set that matches the magnetic field strength, pulse sequence, and/or TE value of the MRS data to be analyzed, a basis set can be made from MRS data of the water solution phantom of metabolites34 or by using simulation software such as FID-A.104 In addition, to analyze the peaks of metabolites or drugs that are not included in the model spectrum, a basis set that incorporates those model peaks can be created.

**Clinical utility of \(^1\)H-MRS**

Even in the 2010s, the clinical dissemination of \(^1\)H-MRS as a routine diagnostic tool was very slow, and the availability of \(^1\)H-MRS was generally limited to specialized institutions or hospitals with specialists in \(^1\)H-MRS technology. The reasons for the limited clinical use of \(^1\)H-MRS include its technical feasibility, lack of methodological standardization, and difficulties in interpretation. Some MR communities have published several excellent reviews to help establish a methodological and clinical consensus in the 2010s105,106 because the increased availability of 3-T MRI instruments was considered to be an excellent opportunity to promote clinical MRS. Our MRS community in the Japan Society of Magnetic Resonance in Medicine (JSMMR) published a consensus guideline in Japanese on the clinical utility of \(^1\)H-MRS in 2013 (http://ta.kyorin.co.jp/jsmrm/hattuyo/new_MRS_guideline2013.pdf), which can be downloaded from the website of the society. Here, we have attempted to update this consensus guideline to include recent progress related to the technology and its generally accepted findings.

**Physiological changes in metabolites with development and age observed with \(^1\)H-MRS**

The signals of major metabolites observed with \(^1\)H-MRS are affected by brain development and aging, and their concentrations also differ among anatomical cerebral regions. The intensities of Cho and NAA signals are generally higher in white matter than in gray matter, whereas those of Cr, mIns, and Glx are higher in gray matter than in white matter.107,108 Furthermore, the intensities of Cr and Cho signals are usually highest in the cerebellum.108

Many studies have shown that NAA and Cr signals are increased in childhood and that Cho and mIns signals decrease rapidly within the first year of life as development progresses, with a gradual decline until about 20 years of age.107

In a systematic review of the brain metabolite changes measured by \(^1\)H-MRS during healthy aging,109,110 most data were derived from the frontal region and indicated no change in older individuals in 18 studies. However, a meta-analysis
showed a decrease in frontal NAA and increases in parietal Cho and Cr. This review suggested that NAA may decrease, and Cho and Cr increase with age, and more data are therefore needed from older individuals to better characterize the effect of age. Accordingly, metabolite ratios in older people should be interpreted with caution.

**Clinical utility in the diagnosis of brain tumors and tumor-like disorders**

The clinical utility of $^1$H-MRS can largely be classified into five categories: 1) grading of gliomas, 2) evaluation of therapeutic effects, including differentiation between recurrence and radiation necrosis, 3) differentiation between gliomas and brain metastasis, 4) differentiation between cystic tumors and brain abscess, and 5) prediction of isocitrate dehydrogenase (IDH) mutant gliomas using the detection of 2-hydroxyglutarate (2-HG).

For glioma grading, several studies have reported that automated algorithms can classify high- and low-grade gliomas with sensitivity and specificity exceeding 90%. However, the accuracy of the differentiation between grade III and IV is lower. Regarding the evaluation of therapeutic effects, increases in Cho or in the signal ratios of Cho/Cr and Cho/NAA were related to tumor recurrence or a low therapeutic effect, whereas low levels of Lac and Lip were found in good responders to tamoxifen. The accuracy of the differentiation between gliomas and metastasis was 60%–80% and lower than that of the grading of glioma (about 90%). The ability to differentiate between gliomas and metastasis was suggested to be related to a greater increase in lipids in metastasis than in gliomas. Cystic tumors and abscess were successfully differentiated using the signal derived from succinate, acetate, alanine, and glycine, with 96% sensitivity and 100% specificity.

IDH mutant gliomas have recently received more attention due to their better prognosis than IDH wild-type gliomas. IDH overproduces 2-HG, which is a suitable biomarker of IDH mutant glioma. 2-HG has five protons with a complicated J-coupling interaction and shows complicated multiplet signals at about 1.9 ppm, 2.3 ppm, and 4.0 ppm. These signals usually overlap the major peaks of NAA, Glx, and Cr, and accurate detection of 2-HG by $^1$H-MRS is therefore difficult and is still undergoing refinement. Thus far, several $^1$H-MRS methods have been proposed, such as a short TE or long TE conventional $^1$H-MRS sequence using prior-knowledge spectral analysis software (e.g., LCModel), the difference editing technique, and the 2D method. Most of the studies have been conducted using a conventional sequence with specific analysis software and showed higher sensitivity than specificity, with ranges of 77%–100% for sensitivity and 72%–100% for specificity. Although a few studies have been performed with the difference editing technique, a recent prospective study using spectral editing MRS with jMRUI software showed a sensitivity of 80% and specificity of 81%. Preoperative edited MRS also appears to be able to help identify IDH mutant gliomas with high specificity, but the accuracy requires improvement.

**Clinical utility of $^1$H-MRS in neurodegenerative diseases**

Neurodegenerative diseases, which include Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, and multiple system atrophy, have been studied using clinical $^1$H-MRS. $^1$H-MRS can be used to detect characteristic metabolic changes, especially in metabolic or degenerative pediatric diseases, such as lysosomal storage disease, peroxisome disease, and mitochondria disease. $^1$H-MRS is sometimes more useful than MRI-mediated morphological diagnosis in certain metabolic or degenerative diseases, and its utility can be classified into the following four categories. Although these categories comprise rare diseases, $^1$H-MRS plays significant roles in their clinical diagnosis.

**Deficiency in Cr signals**

Three metabolite diseases have thus far been reported in this category. Guanidinoacetate methyltransferase (GAMT) deficiency and creatine transporter (CRTR) deficiency show a loss of Cr signal and an increase in guanidinoacetate, which is a precursor of Cr, with signals appearing at about 3.7–3.9 ppm. Arginine:glycine amidinotransferase (AGAT) deficiency also shows a loss of Cr signal, with no increased signal from metabolites.

**Increased NAA signal**

Canavan disease and Salla disease are the two representative diseases in this category. Canavan disease causes decreased activity in aspartoacylase, which induces NAA accumulation. In addition, Cr and Cho are decreased and mlns is increased. Salla disease is an abnormality in sialic acid metabolism that involves the accumulation of n-acetylneuraminic acid (NANA), whose signal is close to that of NAA, which complicates their differentiation. This disease may be recognized as an increase in NAA signal, especially at 1.5-T. Furthermore, Pelizaeus-Merzbacher...
disease is also known by an increase in NAA and Cr, and decrease in Cho.

**Appearance of specific peaks that cannot usually be identified**

a) Sjögren–Larsson syndrome: This disease is an abnormality in lipid metabolism involving a deficiency in fatty aldehyde dehydrogenase. The peaks derived from long-chain fatty alcohols are found at 0.9 and 1.3 ppm. A peak is observed at 0.9 ppm with a short TE sequence due to the short T2 values of this metabolite.\(^{131}\)

b) Succinate dehydrogenase deficiency: This disease is a type of mitochondrial encephalopathy. The peak of succinate is found at 2.4 ppm, in addition to the Lac peak.\(^{132}\)

c) Maple syrup urine disease: This disease is an abnormality in branched chain amino acid metabolism. The peaks of valine, leucine, and isoleucine are observed at 0.9–1.0 ppm, in addition to a decrease in NAA and an increase in Lac.\(^{133}\)

d) Galactosemia: This disease is caused by an abnormality in an enzyme related to galactose metabolism. The peaks of galactitol are found at 3.67 and 3.74 ppm.\(^{134}\)

e) Nonketotic hyperglycinemia: This disease is due to an abnormality in the glycine cleavage enzyme. A peak in glycine is observed at 3.55 ppm, which overlaps with that of m1ns.\(^{135}\) However, the T2 value of glycine is much longer than that of m1ns, which means that the peak at 3.55 ppm is usually observed in these patients with a long TE sequence. There are no abnormalities in NAA, Cr, and Cho with this disease.

f) Ribose-5-phosphate isomerase deficiency: This disease involves an abnormality in polyol metabolism. \(^1\)H-MRS shows peaks of D-arabitol and ribitol at 3.6 and 3.8 ppm, respectively, which reflect the accumulation of polyols.\(^{136}\)

g) Sandhoff disease: This lysosomal disease is caused by a deficiency in hexosaminidases A and B. The peak of N-acetyhexosamine is found at 2.07 ppm, and \(^1\)H-MRS also detects a decrease in NAA and increase in m1ns.\(^{137}\)

h) GABA transaminase deficiency: Glu is metabolized to succinate from GABA through succinic semialdehyde. This pathway is called the GABA shunt. This disease causes an increase in GABA and \(^1\)H-MRS can show the increase in GABA signal.\(^{27}\)

i) 3-hydroxy-3-methylglutaryl-CoAlyases (HMG-CoA) deficiency: HMG-CoA is transferred to acetyl-CoA and individuals with this deficiency show a peak at 2.42 ppm from 3-hydroxyisovalerate and 3-hydroxy-3-methylglutarate.\(^{138}\) In addition, \(^1\)H-MRS also identifies a decrease in NAA and increases in Cho and m1ns.

**Clinical studies of developmental disorders**

Developmental disorders, including autism spectrum disorder, are an important target for clinical pediatric investigation and many studies have reported pathophysiological changes in this disorder using \(^1\)H-MRS. However, the difference in metabolites between developmental disorder and normal development has not been characterized, and \(^1\)H-MRS is not considered useful for the diagnosis of this disorder. On the other hand, oxytocin has recently been reported to be useful for improving autistic behavior, with its effect revealed in a randomized controlled trial using \(^1\)H-MRS and functional MRI.\(^{139}\) \(^1\)H-MRS may be useful for evaluating the improvement in brain function with some medications.

**Clinical utility of \(^1\)H-MRS in psychological disorders**

**Schizophrenia**

Of psychological disorders, schizophrenia is the most popular target for clinical \(^1\)H-MRS. The main findings of schizophrenia are decreased NAA or NAA/Cr in the frontal lobe, thalamus, hippocampus, and temporal lobe.\(^{140,141}\) On the other hand, there are no significant differences in Cr and Cho between schizophrenic and healthy individuals. However, these findings are not specific to schizophrenia alone, and the utility of \(^3\)H-MRS in clinical diagnosis remains low.

**Major depression**

The number of published studies concerning major depression is lower than that for schizophrenia, and there is no difference in NAA between individuals with major depression and healthy people in most previous work. Some studies suggested a decrease in Cho/Cr in the basal ganglia and a decrease in Glx in the frontal lobe,\(^{142,143}\) and one study indicated a decrease in GABA in the posterior lobe with a 3-T MRI instrument.\(^{144}\)

**Bipolar disorders and anxiety disorders**

There are, thus far, no consistent findings of \(^1\)H-MRS in bipolar disorder and anxious disorder. Several studies showed decreased NAA or NAA/Cr in the basal ganglia and hippocampus in bipolar disorder,\(^{145}\) but others reported no change in NAA. In anxiety disorder, functional MRI suggested abnormalities in the orbitofrontal cortex, caudate nucleus, and thalamus, but there is no consensus on the changes in metabolites observed with \(^1\)H-MRS. The utility of \(^1\)H-MRS in bipolar and anxiety disorders is limited to the clinical diagnosis and evaluation of therapeutic efficacy.

**Utility of \(^3\)H-MRS in demyelinating diseases**

**Multiple sclerosis, clinically isolated syndrome, and neuromyelitis optica spectrum**

The utility of \(^3\)H-MRS in the diagnosis of multiple sclerosis (MS) can be summarized as follows: 1) comprehension of the pathological changes in the plaques and normal-appearing white matter (NAWM); 2) evaluation of the therapeutic efficacy and monitoring of the clinical course; and 3) prediction of the transformation from clinically isolated syndrome (CIS). The typical findings of MS are increases in Cho, Lac,
Lip, mLns, and Glu and a decrease in NAA in the acute phase; in the chronic phase, the decrease in NAA and the increase in mLns continue, but the signals of Lac, Cho, and Lip gradually normalize. The increase in Glu is limited in the acute phase and may be related to Glu-associated axonal injury and toxicity. In particular, a prominent increase in Glx has been found in tumefactive MS. One study determined an increase in mLns only in MS plaques, and not in NAWM, and mLns may be used to differentiate between MS plaques and NAWM. Therapy responders showed an increase in NAA/ Cr. Several studies reported predictors of the transformation from CIS to MS, and useful predictors may be a significant decrease in NAA in NAWM in the early phase and an increase in mLns.

1H-MRS studies in patients with neuromyelitis optica (NMO) spectrum disorder are still limited, but most of the studies found that the differentiating finding of NMO from MS is the lack of metabolite abnormalities in NAWM in patients with NMO, except for mLns.

**Acute ischemic disease**

Multiple studies have evaluated acute ischemic lesions with 1H-MRS, with decreased NAA and increased Lac consistent findings in acute ischemia, which are related to mitochondrial function and energy failure. One study reported an increase in Lac in the ischemic lesion before the appearance of a high signal in diffusion-weighted imaging. However, no study has determined the level of metabolites on 1H-MRS at which thrombolysis therapies should be applied, and there is no consensus on a suitable quantification method for application to acute ischemic diseases. To avoid time-consuming processes that delay clinical decision-making, further improvements in the measurement time and simplification of the procedure for accurate quantification are required to enable a multicenter prospective study to determine the threshold for the application of thrombolysis in patients with acute ischemic attacks.

**Nuclei other than protons possibly useful in clinical MRS**

Besides protons, all nuclei with a magnetic moment can theoretically be used for nuclear magnetic resonance (NMR). Since the NMR frequency of each nucleus in a static magnetic field is different, it is necessary to install a transmission and reception system in the MR system and to prepare coils that support the frequency. In vivo MRS of nuclei other than protons has been performed for decades, but its application to in vivo humans has been enabled by the recent increase in static magnetic field strength and advances in fast and efficient sampling and reconstruction techniques. The nuclei other than protons that may be useful in clinical MRS in the coming years are 13C, 17O, 23Na, and 31P. Their nuclear spin properties are summarized in Table 2. Relative receptivity is obtained with the following equation:

\[
R_A(X) = \frac{\gamma(X)^3}{\gamma(A)^3} \times \frac{I(X)(I(X)+1)}{I(A)(I(A)+1)} \times \frac{N_{ab}(X)}{N_{ab}(A)}
\]  

where \(R_A(X)\) is the relative receptivity of nucleus X, A is a reference nucleus such as 1H, \(\gamma\) is the gyromagnetic ratio, I is the spin quantum number, and \(N_{ab}\) is natural abundance. 13C: Its natural abundance is about 1%. Oral or intravenous administration of labeled [1-13C] D-glucose and/or [2-13C] urea has been used to monitor the cerebral tricarboxylic acid (TCA) cycle, the Glu–Gln cycle, the metabolism from glucose to amino acids in the brain, the cerebral metabolic rate of oxygen consumption (CMRO2), and the amount of glucose and glycogen in the liver. With the hyperpolarization (HP) technique, 13C-labeled substances increase their MRI signals at a rate of > 10000. [1-13C] Pyruvate has been approved for use in clinical HP studies by the US Food and Drug Administration and has been used to monitor some metabolic pathways, such as glycolysis, the TCA cycle, and amino acid biosynthesis. In vivo human studies have reported metabolic changes in patients with prostate cancer, brain tumor, or breast cancer. Other 13C HP probes used comprise endogenous biomolecules such as [2-13C] pyruvate for probing mitochondrial metabolism and 13C urea for imaging perfusion. 17O: 17O has a spin of 5/2, but the 17O2 gas phase and 17O2 dissolved in water have strong paramagnetism and hence are undetectable in 17O NMR. The 17O signal becomes detectable only when 17O is incorporated into water. 17O has been used to measure the CMRO2 and as a contrast agent. There are two types of 17O-based NMR approaches. One approach involves the direct detection of 17O signal from H217O by intravenous injection of H217O or by inhalation of 17O2 gas, which is converted to H217O via oxidative phosphorylation in the brain. The second approach is to indirectly detect 17O with 1H-MRI. The protons in H217O have various Larmor frequencies due to scalar coupling with O-17. The chemical exchange of water protons among H217O and H216O makes the T2 of the water protons shorter. As a result, the T2-weighted imaging signal intensity of the region including H217O is lower than that containing only H216O. Therefore, it is used to observe water flow by dynamic T2-weighted 1H-MRI. 23Na: Its natural abundance is 100%. 23Na has a spin of 3/2, which causes electrostatic field sensitivity and fast T2* signal decay. 23Na is endogenous to human tissue and can be imaged without external contrast. The concentration of sodium ions (Na+) is reported to be raised in solid tumors, and in vivo human 23Na-MRI studies have been conducted in patients with brain tumor, breast tumors, prostate cancer, and serous ovarian cancer.
31P: Its natural abundance is 100%. In 1H-MRS, Cho, phosphocholine (PCho), and glycerophosphocholine are observed as total Cho, with 1H from the methyl group (-CH3) having almost the same chemical shift value (3.2 ppm). However, 31P-MRS, PCho, and glycerophosphocholine have a phosphate group, and the chemical shift value of each 31P is different and individual quantification is possible. In vivo 31P-MRS provides information on energy metabolism, cell membrane, and pH by monitoring peaks, such as adenosine triphosphate and phosphocreatine, phosphomonoesterase and phosphodiesterase, and inorganic phosphate, respectively. Especially in cancer, Cho phospholipid metabolism, particularly PCho and tCho, are elevated and can be used in cancer diagnosis and staging by using 31P-MRS.

Acknowledgment

The authors of the “Consensus Guidelines for the Clinical Utility of proton MRS” published in 2013 [http://fa.kyorin.co.jp/jsmrm/haifuyo_new_MRS_guideline2013.pdf] were Drs. Masaharu Ida, Yasushi Kaji, Hirohiko Kimura, Mariko Toyooka, Toshinori Hirai, Hitoshi Kubo, Juynnichi Takanashi, Takayuki Obata, Noriko Aida, Masafumi Harada, Kaori Furutani, and Satsuki Sumitani.

Funding

The authors thank Dr. Tsuyoshi Matsuda for his advice on the contents. MT is supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI [Grant Numbers 15K09943 and 19K08213].

Conflicts of Interest

The authors have no conflicts of Interest.

References

1. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46:531–540.
2. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13:129–153.
3. Parsons MW, Li T, Barber PA, et al. Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology 2000; 55:498–505.
4. Caramanos Z, Narayan S, Arnold DL. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005; 128:2483–2506.
5. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81:89–131.
6. Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 2008; 70:1353–1357.
7. Panigraphy A, Nelson MD, Blüml S. Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications. Pediatr Radiol 2010; 40:28–30.
8. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993; 30:424–437.
9. Voet D, Voet JG, Pratt CW. Fundamentals of Biochemistry: Life at the Molecular Level, 5th ed. Hoboken:Wiley, 2016.
10. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011; 11:835–848.
11. Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwalla ZM. Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn 2015; 15:735–747.
12. Shen J, Petersen KF, Behar KL, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A 1999; 96:8235–8240.
13. Verkhratsky A, Butt A. Glial Neurobiology: A textbook. Chichester:John Wiley & Sons, 2007.
14. Heindel W, Kugel H, Roth B. Noninvasive detection of increased glycine content by proton MR spectroscopy in the brains of two infants with nonketotic hyperglycinemia. AJNR Am J Neuroradiol 1993; 14:629–635.
15. Strange K, Emma F, Paredes A, Morrison R. Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 1994; 12:35–43.
16. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49:223–232.
17. Barker PB, Bizzi A, Stefano ND, Gullapalli R, Lin DDM. Clinical MR Spectroscopy: Techniques and Applications. New York:Cambridge University Press, 2009.
18. Bottomley PA, Griffiths JR, Harris RK, et al. Handbook of magnetic resonance spectroscopy in vivo: MRS theory, practice and applications. Chichester:John Wiley & Sons, 2016.

19. Detre JA, Wang ZY, Bogdan AR, et al. Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol 1991; 29:218–221.

20. Mathews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993; 43:2484–2490.

21. Barkovich AJ, Good WV, Koch TK, Berg BO. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol 1993; 14:1119–1137.

22. Leth H, Toft PB, Pryds O, Peitersen B, Lou HC, Henriksen O. Brain lactate in preterm and growth-retarded neonates. Acta Paediatr 1995; 84:495–499.

23. Rinholt JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, Attwell D. Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci 2011; 31:538–548.

24. Xu D, Bonifacio SL, Charlton NN, et al. MR spectroscopy of normative premature newborns. J Magn Reson Imaging 2011; 33:306–311.

25. Tomiyasu M, Aida N, Shibasaki J, et al. Normal lactate concentration range in the neonatal brain. Magn Reson Imaging 2016; 34:1269–1273.

26. Murali-Manohar S, Borbath T, Wright AM, Soher B, Mekle R, Henning A. T2 relaxation times of macromolecules and metabolites in the human brain at 9.4 T. Magn Reson Med 2020; 84:542–558.

27. Tsuji M, Aida N, Obata T, et al. A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis 2010; 33:85–90.

28. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987; 508:333–348.

29. Rothman DL, Petroff OA, Behar KL, Mattsson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 1993; 90:5662–5666.

30. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998; 11:266–272.

31. Terpstra M, Henry PG, Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCMModel analysis of difference-edited spectra. Magn Reson Med 2003; 50:19–23.

32. Puts NA, Edden RA. In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc 2012; 60:29–41.

33. Freeman R. Sensitivity. In: A handbook of nuclear magnetic resonance, 2nd ed. Harlow:Addison-Wesley Longman, 1997; 248–255.

34. Provencher S. LCMModel & LCMgui User’s Manual. http://sprovencher.com/pub/LCMModel/manual/manual.pdf (Accessed: November 14, 2021)

35. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004; 17:361–381.

36. Farrar T, Becker E. Basic concepts in NMR. In: Pulse and fourier transform NMR. New York:Academic Press, 1971; 1–17.

37. Li BS, Regal J, Gonen O. SNR versus resolution in 3D 1H MRS of the human brain at high magnetic fields. Magn Reson Med 2001; 46:1049–1053.

38. Mlynárik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 2001; 14:325–331.

39. Madan A, Ganji SK, An Z, et al. Proton T2 measurement and quantification of lactate in brain tumours by MRS at 3 Tesla in vivo. Magn Reson Med 2015; 73:2094–2099.

40. Zhang Y, Shen J. Simultaneous quantification of glutamate and glutamine by J-modulated spectroscopy at 3 Tesla. Magn Reson Med 2016; 76:725–732.

41. Elster AD. Questions and answers in MRI. Toronto:Mosby, 1994.

42. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med 1993; 29:804–811.

43. Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts’ consensus recommendations. NMR Biomed 2021; 34:e4257.

44. Pfeuffer J, Tkác I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 1999; 141:104–120.

45. de Graaf RA, Brown PB, McIntyre S, Nixon TW, Behar KL, Rothman DL. High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo. Magn Reson Med 2006; 56:386–394.

46. Lunsing RJ, Strating K, de Koning TJ, Sijens PE. Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders. Eur Radiol 2017; 27:976–984.

47. Cheong JL, Cady EB, Penrice J, Wyatt JS, Cox IJ, Robertson NJ. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am J Neuroradiol 2006; 27:1546–1554.

48. Kendall GS, Melbourne A, Johnson S, et al. White matter NAA/Cho and Cho/Cr ratios at MR spectroscopy are predictive of motor outcome in preterm infants. Radiology 2014; 271:230–238.

49. Lally PJ, Montaldo P, Oliveira V, et al. MARBLE consortium. Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. Lancet Neurol 2019; 18:35–45.

50. Kaiser LG, Young K, Matson GB. Numerical simulations of localized high field 1H MR spectroscopy. J Magn Reson 2008; 195:67–75.

51. Ganji SK, Banerjee A, Patel AM, et al. T2 measurement of J-coupled metabolites in the human brain at 3T. NMR Biomed 2012; 25:523–529.

52. Ross BD, Radda GK, Gadian DG, Rocker G, Esiri M, Falconer-Smith J. Examination of a case of suspected McArdle’s syndrome by 31P nuclear magnetic resonance. N Engl J Med 1981; 304:1338–1342.
53. Chance B, Eleff S, Leigh JS, Sokolow D, Sapega A. Mitochondrial regulation of phosphocreatine/inorganic phosphate ratios in exercising human muscle: a gated 31P NMR study. Proc Natl Acad Sci U S A 1981; 78:6714–6718.

54. in ’t Zandt H, van Der Graaf M, Heerschap A. Common processing of in vivo MR spectra. NMR Biomed 2001; 14:224–232.

55. Henning A, Fuchs A, Murdoch JB, Boesiger P. Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for (1) H-MRSIof the human brain at 7 T with minimal signal loss. NMR Biomed 2009; 22:683–696.

56. Maudsley AA,Govind V,Gold SG,Harris L,Sheriff S. Longitudinal MR Spectroscopy Shows Altered Metabolism in Traumatic Brain Injury. J Neuroimaging 2017; 27:562–569.

57. Nassirpour S, Chang P, Henning A. High and ultra-high resolution metabolite mapping of the human brain using 1H FID MRSI at 9.4T. Neuroimage 2018; 168:211–221.

58. Hangel G,Strasser B,Považan M,et al.Ultra-high resolution brain metabolite mapping at 7 T by short-TR Hadamard-encoded FID-MRSI. Neuroimage 2018; 168:199–210.

59. Nassirpour S, Chang P, Avdievitch N, Henning A. Compressed sensing for high-resolution nonlipid suppressed 1H FID MRSI of the human brain at 9.4T. Magn Reson Med 2018; 80:2311–2325.

60. Bund C, Lefebvre F, Schott R, et al. Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. Magn Reson Imaging 2018; 52:75–83.

61. Maudsley AA, Andronesi OC, Barker PB, et al. Advanced magnetic resonance spectroscopic neuroimaging: Experts’ consensus recommendations. NMR Biomed 2021; 34:e4309.

62. Frahm J,Bruhn H,Gyngell ML,Merboldt KD,Hänicke W,Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989; 9:79–93.

63. Alger JR,Sillerud LO,Behar KL,et al.In vivo carbon-13 nuclear magnetic resonance studies of mammals. Science 1981; 214:660–662.

64. Bottomley PA,Foster TB,Darrow RD. Depth-resolved sur- face coil spectroscopy (DRESS) for in vivo 1H, 31P and 13C nuclear magnetic resonance studies of mammals. Science 1981; 214:660

65. Bottomley PA,Drayer BP,Ozgur M,et al.Chronically ill patients with type 2 diabetes. Circulation 2003; 107:3040–3046.

66. Scheuermann-Freestone M,Madsen PL,Manners D,et al.Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107:3040–3046.

67. Tomiyasu M,Obata T,Nishi Y,et al.Monitoring of liver glycogen synthesis in diabetic patients using carbon-13 MR spectroscopy. Eur J Radiol 2010; 73:300–304.

68. Tkáč I,Deechand D,Dreher W,et al.Water and lipid suppression techniques for advanced 1H MRS and MRSI of the human brain: Experts’ consensus recommendations. NMR Biomed 2021; 34:e4459.

69. Haase A,Frahm J,Hänicke W,Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985; 30:341–344.

70. Moonen CTW, Van Zijl PCM. Highly effective water suppression for in vivo proton NMR spectroscopy (DRYSTEAM). J Magn Reson 1990; 88:28–41.

71. Klose U.In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 1990; 14:26–30.

72. Doddrell DD,Galloway GJ,Brooks WM,et al.The utilization of two frequency-shifted sinc pulses for performing volume-selected in vivo NMR spectroscopy. Magn Reson Med 1986; 3:970–975.

73. Tran TK,Vigneron DB,Sailasuta N,et al.Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000; 43:23–33.

74. Choi IY,Tkac I,Gruetter R.Single-shot, three-dimensional “non-echo” localization method for in vivo NMR spectroscopy. Magn Reson Med 2000; 44:387–394.

75. Hahn EL.Spin echoes. Phys Rev 1950; 80:580–594.

76. McBirnie D,Moore EA,Graves MJ,Prince MR.The parallel universe: parallel imaging and novel imaging techniques. In: MRI from picture to proton, 3rd ed. New York: Cambridge University Press, 2017; 225–250.

77. Schar M,Strasser B,Dydk U.Chemical shift imaging with phase and sensitivity encoding. In: Bottomley PA,Griffiths JR,et al. Handbook of magnetic resonance spectroscopy in vivo, 1st ed. Chichester:Wiley, 2016; 121–139.

78. LCM. http://s-provencher.com/lcmode.shtml (Accessed: November 14, 2021)

79. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30:672–679.

80. jMRUI. http://www.jmrui.eu/welcome-to-the-new-mrui-website/ (Accessed: May 29, 2021)

81. Jabłoński M, Starčuková J, Starčuk Z. Processing tracking in jMRUI software for magnetic resonance spectra quantitation reproducibility assurance. BMC Bioinformatics 2017; 18:56.

82. Tarquin. http://tarquin.sourceforge.net/index.php (Accessed: November 14, 2021)

83. Wilson M,Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med 2011; 65:1–12.

84. Poulet JB,Sima DM, Van Hulffel S.MRS signal quantitation: a review of time- and frequency-domain methods. J Magn Reson 2008; 195:134–144.

85. Wilson M. Adaptive baseline fitting for 1H MR spectroscopy analysis. Magn Reson Med 2021; 85:13–29.

86. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 2010; 15:308–318.

87. Aoki Y, Abe O, Yahata N, et al. Absence of age-related prefrontal NAA change in adults with autism spectrum disorders. Transl Psychiatry 2012; 2:e178.

88. Chang L, Ernst T,Poland RE,Jenden DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996; 58:2049–2056.

89. Williams LA,Gelman N,Picot PA,et al.Neonatal brain: regional variability of in vivo MR imaging relaxation rates at 3.0 T—initial experience. Radiology 2005; 235:595–603.
90. Gwan K, Edzes HT. Water in brain edema. Observations by the pulsed nuclear magnetic resonance technique. Arch Neurol 1975; 32:462–465.

91. Just M, Thelen M. Tissue characterization with T1, T2, and proton density values: results in 160 patients with brain tumors. Radiology 1988; 169:779–785.

92. Laule C, Vavasour IM, Moore GR, et al. Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study. J Neurol 2004; 251:284–293.

93. Frahm J, Bruhn H, Gygell ML, Merboldt KD, Hänicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989; 11:47–63.

94. Christiansen P, Toft P, Larsson HB, Stubgaard M, Henriksen O. The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 1993; 11:799–806.

95. Manton DJ, Lowry M, Blackband SJ, Horsman A. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours. NMR Biomed 1995; 8:104–112.

96. Ethofer T, Mader I, Seeger U, et al. Comparison of longitudinal metabolite relaxation times in different regions of the human brain at 1.5 and 3 Tesla. Magn Reson Med 2003; 50:1296–1301.

97. Ernst T, Kreis R, Ross BD. Absolute Quantitation of Water and Metabolites in the Human Brain. I. Compartments and Water. J Magn Reson, Series B 1993; 102:1–8.

98. Michaelis T, Merboldt KD, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993; 187:219–227.

99. Mekle R, Mlynárík V, Gambarota G, Hergt M, Krueger G, Michaelis T, Merboldt KD, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993; 187:219–227.

100. Marjańska M, Auerbach EJ, Valabrègue R, Van de Moortele PF, Adriany G, Garwood M. Localized 1H NMR spectroscopy in different regions of human brain in vivo at 7 T: T2 relaxation times and concentrations of cerebral metabolites. NMR Biomed 2012; 25:332–339.

101. Považan M, Strasser B, Hangel G, et al. Simultaneous mapping of metabolites and individual macromolecular components via ultra-short acquisition delay 1 H MRSI in the brain at 7T. Magn Reson Med 2018; 79:1231–1240.

102. Giapitzakis IA, Avdievich N, Henning A. Characterization of macromolecular baseline of human brain using metabolite cycled semi-LASER at 9.4T. Magn Reson Med 2018; 80:462–473.

103. Lange T, Dydk U, Roberts TP, Rowley HA, Bjeljac M, Boesiger P. Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006; 27:895–901.

104. Simpson R, Devenyi GA, Jezzard P, Hennessy TJ, Near J. Advanced processing and simulation of MRS data using the FID appliance (FID-A)-An open source, MATLAB-based toolkit. Magn Reson Med 2017; 77:23–33.

105. Oz G, Alger JR, Barker PB, et al. MRS Consensus Group. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014; 270:658–679.

106. Wilson M, Andronesi O, Barker PB, et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magn Reson Med 2019; 82:527–550.

107. Astrakas LG, Argyropoulou MI. Key concepts in MR spectroscopy and practical approaches to gaining biochemical information in children. Pediatr Radiol 2016; 46:941–951.

108. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998; 39:53–60.

109. Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 2009; 30:353–363.

110. Gleeland C, Pipingas A, Scholey A, White D. Neurochemical changes in the aging brain: A systematic review. Neurosci Biobehav Rev 2019; 98:306–319.

111. Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neuropsych 2003; 98:74–81.

112. Sankar T, Caramanos Z, Assina R, et al. Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. J Neurooncol 2008; 90:63–76.

113. Opstad KS, Murphy MM, Wilkins PR, Bell BA, Griffiths JR, Howe FA. Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004; 20:187–192.

114. Majós C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003; 13:582–591.

115. Mishra AM, Gupta RK, Jaggi RS, et al. Role of diffusion-weighted imaging and in vivo proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing intracranial cystic mass lesions. J Comput Assist Tomogr 2004; 28:540–547.

116. Kim H, Thompson RB, Hanstock CC, Allen PS. Variability of metabolite yield using STEAM or PRESS sequences in vivo at 3.0 T, illustrated with myo-inositol. Magn Reson Med 2005; 53:760–769.

117. Branzoli F, Di Stefano AL, Capelle L, et al. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol 2018; 20:907–916.

118. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo magnetic resonance spectroscopy. Sci Transl Med 2012; 4:116ra4.

119. Kim S, Salamon N, Jackson HA, Bluml S, Panigrahy A. PET imaging in pediatric neuroradiology: current and future applications. Pediatr Radiol 2010; 40:82–96.

120. Nguyen TB, Melkus G, Taccone M, et al. Preoperative Determination of Isocitrate Dehydrogenase Mutation in
in vitro (ex vivo) correlation. Eur Radiol 2002; 12:858–861.

136. Hucker JH, Verhoeven NM, Struys EA, Salomons GS, Jakobs C, van der Knaap MS. Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. Am J Hum Genet 2004; 74:745–751.

137. Wilken B, Dechent P, Hanefeld F, Frahm J. Proton MRS of a child with Sandhoff disease reveals elevated brain hexosamine. Eur J Paediatr Neurol 2008; 12:56–60.

138. Yalcinkaya C, Dincer A, Gunduz E, Ficicioglu C, Kozer N, Aylid A. MRI and MRS in HMG-CoA lyase deficiency. Pediatr Neurol 1999; 20:375–380.

139. Aoki Y, Watanabe T, Abe O, et al. Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial. Mol Psychiatry 2015; 20:447–453.

140. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008; 33:2456–2466.

141. Molina V, Sánchez J, Sanz J, et al. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. Eur Psychiatry 2007; 22:505–512.

142. Gabbay V, Hess DA, Liu S, Babb JS, Klein RG, Gonen O. Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MRS spectroscopy study. Am J Psychiatry 2007; 164:1881–1889.

143. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47:305–313.

144. Bhagwagar Z, Wylezinska M, Jezzard P, et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007; 61:806–812.

145. Olivera RL, Caetano SC, Fonseca M, et al. Low levels of N-acetyl aspartate in the left dorsolateral prefrontal cortex of pediatric bipolar patients. J Child Adolesc Psychopharmacol 2007; 17:461–473.

146. Rovira A, León A. MR in the diagnosis and monitoring of multiple sclerosis: an overview. Eur J Radiol 2008; 67:409–414.

147. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28:277–287.

148. Khan O, Shen Y, Bao F, et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H-MRS monitoring in multiple sclerosis. J Neuroimagng 2008; 18:314–319.

149. Wiatjes MP, Harzheim M, Lutterbey GG, Klotz L, Schild HH, Träber F. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28:1517–1522.
150. Summers M, Swanton J, Fernando K, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008; 79:955–958.

151. Duan Y, Liu Z, Liu Y, et al. Metabolic changes in normal-appearing white matter in patients with neuromyelitis optica and multiple sclerosis: a comparative magnetic resonance spectroscopy study. Acta Radiol 2017; 58:1132–1137.

152. Nicoli F, Lefur Y, Denis B, Ranjeva JP, Confort-Gouny S, Cozzone PJ. Metabolic counterpart of decreased apparent diffusion coefficient during hyperacute ischemic stroke: a brain proton magnetic resonance spectroscopic imaging study. Stroke 2003; 34:82–87.

153. Stengel A, Neumann-Haefelin T, Singer OC, et al. Multiple spin-echo spectroscopic imaging for rapid quantitative assessment of N-acetyl aspartate and lactate in acute stroke. Magn Reson Med 2004; 52:228–238.

154. Dani KA, An L, Henning EC, Shen J, Warach S; National Institute of Neurological Disorders and Stroke Natural History of Stroke Investigators. Multivoxel MR spectroscopy in acute ischemic stroke: comparison to the stroke protocol MRI. Stroke 2012; 43:2962–2967.

155. Abragam A. Principles of nuclear magnetism. New York: Oxford University Press, 1983; 648.

156. Konstandin S, Nagel AM. Measurement techniques for magnetic resonance imaging of fast relaxing nuclei. MAGMA 2002; 58:1132–1137.

157. Bogner W, Otazo R, Henning A. Accelerated MR spectroscopic imaging. Magn Reson Med 2004; 52:228–238.

158. Tailor DR, Baumgardner JE, Regatte RR, Leigh JS, Reddy DL. Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and fMRI. Magn Reson Med 2004; 52:228–238.

159. Watanabe H, Noda Y, Takegoshi K. Elemental analysis order to nuclear-spin magnetization by chemical reaction and nuclear magnetic resonance. Phys Rev Lett 1986; 57:2645–2648.

160. Chen W, Zhu XH, Gruetter R, Seaquist ER, Adriany G, Takeda K, Ichijo N, Noda Y, Takegoshi K. Elemental analy-

161. Zhu XH, Lu M, Chen W. Quantitative imaging of brain metabolites using (1)H–[(13)C] MRS and fMRI. Magn Reson Med 2001; 45:349–355.

162. Beckmann N, Fried R, Turkalj I, Seelig J, Keller U, Stalder G. Noninvasive observation of hepatic glycogen formation in man by 13C MRS after oral and intravenous glucose administration. Magn Reson Med 1993; 29:583–590.

163. Chen W, Zhu XH, Gruetter R, Seaquist ER, Adriany G, Ugurbil K. Study of tricarboxylic acid cycle flux changes in human visual cortex during hemifield visual stimulation using (1)H–[(13)C] MRS and fMRI. Magn Reson Med 2001; 45:349–355.

164. Mason GF, Petersen KE, de Graaf RA, Shulman GI, Rothman DL. Measurements of the anaerobic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13C] and [2-13C] glucose. J Neurochem 2007; 100:73–86.

165. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003; 100:10158–10163.

166. Wang ZJ, Ohlinger MA, Larson PEZ, et al. Hyperpolarized 13C MRI: State of the Art and Future Directions. Radiology 2019; 291:273–284.

167. Nelson SJ, Kurbanevic G, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1–13C]pyruvate. Sci Transl Med 2013; 5:198ra108.

168. Miloushev VZ, Granlund KL, Boltyanskiy R, et al. Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients. Cancer Res 2018; 78:3755–3760.

169. Park I, Larson PEZ, Gordon JW, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patients with Alzheimer’s disease. Magn Reson Med 2018; 80:864–873.

170. Park JM, Josan S, Grafendorfer T, et al. Measuring mitochondrial metabolism in rat brain in vivo using MR Spectroscopy of hyperpolarized [2–13C]pyruvate. NMR Biomed 2013; 26:1197–1203.

171. Josan S, Hurd R, Park JM, et al. Dynamic metabolic imaging of hyperpolarized [2-(13) C]pyruvate using spiral chemical shift imaging with alternating spectral band excitation. Magn Reson Med 2014; 71:2051–2058.

172. Mignon L, Dutta P, Martinez GV, Foroutan P, Gillies RJ, Jordan BF. Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. Cancer Res 2014; 74:686–694.

173. Chen HY, Larson PEZ, Bok RA, et al. Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion. Cancer Res 2017; 77:3207–3216.

174. Pekar J, Litte J, Ruttner Z, et al. In vivo measurement of cerebral oxygen consumption and blood flow using 17O magnetic resonance imaging. Magn Reson Med 1991; 21:313–319.

175. Kwong KK, Hopkins AL, Belliveau JW, et al. Proton NMR imaging of cerebral blood flow using H2(17)O. Magn Reson Med 1991; 22:154–158.

176. Ronen I, Merkle H, Ugurbil K, Navon G. Imaging of H217O distribution in the brain of a live rat by using proton-detected 17O MRI. Proc Natl Acad Sci U S A 1998; 95:12934–12939.

177. Tailor DR, Baumgardner JE, Regatte RR, Leigh JS, Reddy R. Proton MRI of metabolically produced H2 17O using an efficient 17O2 delivery system. Neuroimage 2004; 22:611–618.

178. Zhu XH, Zhang N, Zhang Y, Zhang X, Ugurbil K, Chen W. In vivo 17O NMR approaches for brain study at high field. NMR Biomed 2005; 18:103–109.

179. Atkinson IC, Thulborn KR. Feasibility of mapping the tissue mass corrected bioscale of cerebral metabolic rate of oxygen consumption using 17-oxygen and 23-sodium MR imaging in a human brain at 9.4 T. Neuroimage 2010; 51:723–733.

180. Zhu XH, Lu M, Chen W. Quantitative imaging of brain energy metabolisms and neuroenergetics using in vivo X-
nuclear 2H, 17O and 31P MRS at ultra-high field. J Magn Reson 2018; 292:155–170.

181. Niesporek SC, Umathum R, Lommen JM, et al. Reproducibility of CMRO2 determination using dynamic 17 O MRI. Magn Reson Med 2018; 79:2923–2934.

182. Kudo K, Harada T, Kameda H, et al. Indirect Proton MR Imaging and Kinetic Analysis of 17O-Labeled Water Tracer in the Brain. Magn Reson Med Sci 2018; 17:223–230.

183. Elliott SJ, Bengs C, Kouril K, et al. NMR Lineshapes and Scalar Relaxation of the Water-Endofullerene H217 O@C60. Chemphyschem 2018; 19:251–255.

184. Meiboom S. Nuclear magnetic resonance study of the proton transfer in water. J Chem Phys 1961; 34:375–388.

185. Hopkins AL, Barr RG. Oxygen-17 compounds as potential NMR T2 contrast agents: enrichment effects of H2(17)O on protein solutions and living tissues. Magn Reson Med 1987; 4:399–403.

186. Yeung HN, Lent AH. Proton transverse relaxation rate of 17O-enriched water. Magn Reson Med 1987; 5:87–92.

187. Kwong KK, Xiong J, Kuan WP, Cheng HM. Measurement of water movement in the rabbit eye in vivo using H2(17)O. Magn Reson Med 1991; 22:443–450.

188. Leslie TK, James AD, Zaccagna F, et al. Sodium homeostasis in the tumour microenvironment. Biochim Biophys Acta Rev Cancer 2019; 1872:188304.

189. Poku LO, Phil M, Cheng Y, Wang K, Sun X. 23 Na-MRI as a Noninvasive Biomarker for Cancer Diagnosis and Prognosis. J Magn Reson Imaging 2021; 53:995–1014.

190. Ouwerkerk R, Bleich KB, Gillen JS, Pomper MG, Bottomley PA. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology 2003; 227:529–537.

191. Ouwerkerk R, Jacobs MA, Macura KJ, et al. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat 2007; 106:151–160.

192. Jacobs MA, Stearns V, Wolff AC, et al. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (23Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol 2010; 17:1477–1485.

193. Jacobs MA, Ouwerkerk R, Wolff AC, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, 23 Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat 2011; 128:119–126.

194. Broeke NC, Peterson J, Lee J, et al. Characterization of clinical human prostate cancer lesions using 3.0-T sodium MRI registered to Gleason-graded whole-mount histopathology. J Magn Reson Imaging 2019; 49:1409–1419.

195. Deen SS, Riemer F, McLean MA, et al. Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. Eur J Radiol Open 2019; 6:156–162.

196. Barrett T, Riemer F, McLean MA, et al. Molecular imaging of the prostate: Comparing total sodium concentration quantification in prostate cancer and normal tissue using dedicated 13 C and 23 Na endorectal coils. J Magn Reson Imaging 2020; 51:90–97.

197. Oberhaensli RD, Galloway GJ, Taylor DJ, Bore PJ, Radda GK. Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol 1986; 59:695–699.

198. Liu Y, Gu Y, Yu X. Assessing tissue metabolism by phosphorous-31 magnetic resonance spectroscopy and imaging: a methodology review. Quant Imaging Med Surg 2017; 7:707–726.

199. Griffiths JR, Cady E, Edwards RH, McCready VR, Wilkie DR, Wiltshaw E. 31P-NMR studies of a human tumour in situ. Lancet 1983; 1:1435–1436.

200. Evanochko WT, Sakai TT, Ng TC, et al. NMR study of in vivo RIF-1 tumors. Analysis of perchloric acid extracts and identification of 1H, 31P and 13C resonances. Biochim Biophys Acta 1984; 805:104–116.

201. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007; 120:1721–1730.